Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 5/20 | 0.68 |
| ▸ | HTR2C | P28335 | 5/20 | 0.68 |
| ▸ | HTR7 | P34969 | 8/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CTSK | P43235 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 3/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21883968 | 1.00 | GRIN2B (0.70) | GRIN2BHTR2AHTR2CHTR7CHRM4 | |
| SCHEMBL29756361 | 1.00 | GRIN2B (0.70) | GRIN2BHTR2AHTR2CHTR7CHRM4 | |
| SCHEMBL5532807 | 0.85 | GRIN2B (0.70) | GRIN2BHTR2AHTR2CHTR7CHRM4 | |
| SCHEMBL10924004 | 0.85 | GRIN2B (0.70) | GRIN2BHTR2AHTR2CHTR7CHRM4 | |
| SCHEMBL14892998 | 0.85 | GRIN2B (0.62) | GRIN2BHTR2AHTR2CHTR7CHRM4 | |
| SCHEMBL18669422 | 0.84 | GRIN2B (0.65) | GRIN2BHTR2AHTR2CHTR7CHRM4 | |
| Xestoamine SCHEMBL2271935 | 0.84 | GRIN2B (0.65) | GRIN2BHTR2AHTR2CHTR7CHRM4 | |
| Xestoamine SCHEMBL6087465 | 0.83 | GRIN2B (0.64) | GRIN2BHTR2AHTR2CHTR7CHRM4 | |
| Fenharmane SCHEMBL9695673 | 0.82 | GRIN2B (1.00) | GRIN2BHTR2AHTR2CHTR7CHRM4 | |
| SCHEMBL24506125 | 0.82 | GRIN2B (0.62) | GRIN2BHTR2AHTR2CHTR7CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| EP-3600451-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | Minerva Biotechnologies Corporation (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3535263-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | Sanofi (FR) | 2019-09-11 | — | — | EP | disclosed |
| WO-2018183654-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2004113336-A1 | CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MCL1, CD44, EPCAM | GRIN2B 4259/4885HTR2A 4615/4885HTR2C 4566/4885 |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | GRIN2B 3448/4885HTR2A 4440/4885HTR2C 4453/4885 |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | GRIN2B 3448/4885HTR2A 4440/4885HTR2C 4453/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | GRIN2B 3235/4885HTR2A 3307/4885HTR2C 1923/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | GRIN2B 3448/4885HTR2A 4440/4885HTR2C 4453/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | GRIN2B 3448/4885HTR2A 4440/4885HTR2C 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.